Envision Pharma Group (Envision) has announced today the appointment of Alistair Macdonald to the Envision Board of Directors.
“It’s a pleasure to welcome Alistair to the Envision Board of Directors,” shared Howard Miller, CEO of Envision Pharma Group. “His deep knowledge of executive and operational functions across manufacturing, consulting, clinical, and commercial sectors aligns perfectly with the services we offer our clients. His leadership on the board will position us to continue driving improved outcomes and insights for the life sciences industry.”
Macdonald brings to Envision over 30 years of biopharmaceutical and life sciences experience in executive and operation roles across manufacturing, consulting, clinical, and commercial sectors, and currently serves as an operating partner for GHO Capital.
Recently, he served as the Chief Executive Officer for Syneos Health, a global CRO with over 29,000 employees and operations across 100 countries. Before becoming CEO, Alistair held several leadership roles across the company, including clinical development, global oncology, business development, and alliance management to drive operational excellence.
Prior to his time at Syneos, Macdonald’s career is marked by increasing responsibility and leadership positions at Bovis Lendlease Consulting, supporting companies worldwide, and technical and production management positions at Novartis. He began his career in a dynamic CDMO operation with CCL Pharmaceuticals.
Macdonald will bring a wealth of board leadership experience with this new appointment, as he currently serves as a board member for the Medicines Discovery Catapult Foundation. Previously, he was the director and chairman of the Association of Clinical Research Organizations Board of Directors and a member of Syneos Health’s Board of Directors.
“As a long-time admirer of Envision Pharma Group’s business model, it’s an honor to help them drive the strongest value proposition possible for its customers. I look forward to drawing on my industry and leadership experience in this role to support the crucial work Envision is doing in the life sciences space,” says Macdonald.
